

# Gabriel C Leger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1389370/publications.pdf>

Version: 2024-02-01

34  
papers

1,955  
citations

516215

16  
h-index

500791

28  
g-index

34  
all docs

34  
docs citations

34  
times ranked

2109  
citing authors

#	ARTICLE	IF	CITATIONS
1	Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. <i>Annals of Neurology</i> , 2008, 63, 709-719.	2.8	457
2	Alzheimer's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 167, 231-255.	1.0	415
3	Dopa decarboxylase activity of the living human brain.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 2721-2725.	3.3	177
4	6-[ <sup>18</sup> F]fluoro-L-DOPA Metabolism in Living Human Brain: A Comparison of Six Analytical Methods. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1993, 13, 57-69.	2.4	113
5	Human Striatal L-DOPA Decarboxylase Activity Estimated in vivo Using 6-[ <sup>18</sup> F]fluoro-DOPA and Positron Emission Tomography: Error Analysis and Application to Normal Subjects. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1993, 13, 43-56.	2.4	98
6	Pharmacological Treatment of Alzheimer Disease. <i>Canadian Journal of Psychiatry</i> , 2011, 56, 579-588.	0.9	96
7	Pharmacokinetics of Plasma 6-[ <sup>18</sup> F]Fluoro-L-3,4-Dihydroxyphenylalanine ([ <sup>18</sup> F]FDOPA) in Humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1993, 13, 668-675.	2.4	81
8	Striatal L-DOPA Decarboxylase Activity in Parkinson's Disease In Vivo: Implications for the Regulation of Dopamine Synthesis. <i>Journal of Neurochemistry</i> , 1993, 61, 1538-1541.	2.1	76
9	Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 537-547.	4.9	55
10	Neuropsychiatric Symptom Profile Differs Based on Pathology in Patients with Clinically Diagnosed Behavioral Variant Frontotemporal Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 37, 104-112.	0.7	42
11	Reduction of Circulating 3-O-Methyldopa by Inhibition of Gatechol-O-Methyltransferase With OR-611 and OR-462 in Cynomolgus Monkeys. <i>Clinical Neuropharmacology</i> , 1991, 14, 330-342.	0.2	35
12	3-O-methyldopa administration does not alter fluorodopa transport into the brain. <i>Annals of Neurology</i> , 1992, 31, 638-643.	2.8	35
13	Comparing the Electronic and Standard Versions of the Montreal Cognitive Assessment in an Outpatient Memory Disorders Clinic: A Validation Study. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 93-97.	1.2	33
14	A Systematic Review of Positron Emission Tomography of Tau, Amyloid Beta, and Neuroinflammation in Chronic Traumatic Encephalopathy: The Evidence To Date. <i>Journal of Neurotrauma</i> , 2018, 35, 2015-2024.	1.7	25
15	Effect of catechol-O-methyltransferase inhibition on brain uptake of [ <sup>18</sup> F]fluorodopa: Implications for compartmental modelling and clinical usefulness. , 1998, 30, 351-361.		22
16	Structural and Functional MRI Differences in Master Sommeliers: A Pilot Study on Expertise in the Brain. <i>Frontiers in Human Neuroscience</i> , 2016, 10, 414.	1.0	22
17	Relationship between the Activities of Daily Living Questionnaire and the Montreal Cognitive Assessment. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 4, 43-46.	1.2	21
18	Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. <i>Cell Reports Medicine</i> , 2022, 3, 100607.	3.3	21

#	ARTICLE	IF	CITATIONS
19	Effect of Nitecapone (OR-462) on the Pharmacokinetics of Levodopa and 3-O-Methyldopa Formation in Cynomolgus Monkeys. <i>Clinical Neuropharmacology</i> , 1990, 13, 544-552.	0.2	18
20	Randomized controlled trials in frontotemporal dementia: cognitive and behavioral outcomes. <i>Translational Neurodegeneration</i> , 2014, 3, 12.	3.6	16
21	Toward a revision of criteria for the dementias. , 2007, 3, 428-440.		15
22	Synthesis and biomethylenation of two homoallylically fluorinated oleic acids. <i>Tetrahedron Letters</i> , 1987, 28, 3891-3894.	0.7	14
23	A review on primary progressive aphasia. <i>Neuropsychiatric Disease and Treatment</i> , 2008, Volume 3, 745-752.	1.0	13
24	Neuropsychological Testing in Pathologically Verified Alzheimer Disease and Frontotemporal Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2017, 31, 187-191.	0.6	12
25	Dementia-Like Presentation of Striatal Hypermetabolic State With Antistriatal Antibodies Responsive to Steroids. <i>Archives of Neurology</i> , 2004, 61, 754.	4.9	9
26	Association of Neurofibrillary Tangle Distribution With Age at Onset—Related Clinical Heterogeneity in Alzheimer Disease. <i>Neurology</i> , 2022, 98, .	1.5	9
27	Amygdala sign, a FDG-PET signature of dementia with Lewy Bodies. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 300-303.	1.1	8
28	Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 423-442.	1.3	7
29	Memory Test Performance on Analogous Verbal and Nonverbal Memory Tests in Patients with Frontotemporal Dementia and Alzheimer’s Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2016, 6, 20-27.	0.6	6
30	The Diagnosis and Management of Reversible Dementia Syndromes. <i>Current Treatment Options in Neurology</i> , 2021, 23, 1.	0.7	3
31	Brain-Blood Barrier Removal of DOPA: Role in Regulation of Dopamine Synthesis and Treatment of Parkinson’s Disease. , 1995, , 103-109.		1
32	Progressive aphasia complicated by intracerebral bleeding. , 0, , 71-81.		0
33	Helping the FTD Patient-Caregiver Dyad. <i>Canadian Journal of Neurological Sciences</i> , 2011, 38, 671-672.	0.3	0
34	A-88 * The Confusing Case of the Stuttering Sommelier. <i>Archives of Clinical Neuropsychology</i> , 2014, 29, 536-536.	0.3	0